Global Investment Pulse
  • Investing
  • Stock
  • Business
  • Politics
Business

Pfizer CEO says tariff uncertainty is deterring further U.S. investment in manufacturing, R&D

by admin April 30, 2025
April 30, 2025

Pfizer CEO Albert Bourla on Tuesday said uncertainty around President Donald Trump’s planned pharmaceutical tariffs is deterring the company from further investing in U.S. manufacturing and research and development. 

Bourla’s remarks on the company’s first-quarter earnings call came in response to a question about what Pfizer wants to see from tariff negotiations that would push the company to increase investments in the U.S. It comes as drugmakers brace for Trump’s levies on pharmaceuticals imported into the country — his administration’s bid to boost domestic manufacturing.

“If I know that there will not be tariffs … then there are tremendous investments that can happen in this country, both in R&D and manufacturing,” Bourla said on the call, adding that the company is also hoping for “certainty.”

“In periods of uncertainty, everybody is controlling their cost as we are doing, and then is very frugal with their investment, as we are doing, so that we are prepared for remit. So that’s what I want to see,” Bourla said.

Bourla noted the tax environment, which had previously pushed manufacturing abroad, has “significantly changed now” with the establishment of a global minimum tax of around 15%. He said that shift hasn’t necessarily made the U.S. more attractive, saying “it’s not as good” to invest here without additional incentives or clarity around tariffs.

“Now [Trump] I’m sure — and I know because I talked to him — that he would like to see even a reduction in the current tax regime particularly for locally produced goods,” Bourla said, adding a further decrease would be would be a strong incentive for manufacturing in the U.S.

Unlike other companies grappling with evolving trade policy, Pfizer did not revise its full-year outlook on Tuesday. However, the company noted in its earnings release that the guidance “does not currently include any potential impact related to future tariffs and trade policy changes, which we are unable to predict at this time.”

But on the earnings call on Tuesday, Pfizer executives said the guidance does reflect $150 million in costs from Trump’s existing tariffs.

“Included in our guidance that we didn’t really speak about is there are some tariffs in place today,” Pfizer CFO Dave Denton said on the call.

“We are contemplating that within our guidance range and we continue to again trend to the top end of our guidance range even with those costs to be incurred this year,” he said.

This post appeared first on NBC NEWS

previous post
JetBlue to partner with another U.S. airline in the coming weeks
next post
Charbone Hydrogene annonce les resultats financiers 2024

You may also like

UPS is ‘disposing of’ U.S.-bound packages over customs...

October 13, 2025

China outlines more controls on exports of rare...

October 11, 2025

Paramount acquires Bari Weiss’ The Free Press, naming...

October 8, 2025

Charlie Javice sentenced to 7 years in prison...

October 1, 2025

Video game maker Electronic Arts to be acquired...

October 1, 2025

Nearly 200,000 BMWs recalled over potential fire risk

October 1, 2025

YouTube to pay $24 million to settle Trump...

October 1, 2025

Ben & Jerry’s co-founder resigns, claiming parent company...

September 30, 2025

Ben & Jerry’s co-founder resigns, claiming parent company...

September 29, 2025

Trump says U.S. will impose new tariffs on...

September 29, 2025

Leave a Comment Cancel Reply

Save my name, email, and website in this browser for the next time I comment.

    Join our mailing list to get access to special deals, promotions, and insider information. Your exclusive benefits await! Enjoy personalized recommendations, first dibs on sales, and members-only content that makes you feel like a true VIP. Sign up now and start saving!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • S&P 500 Breaking Out Again: What This Means for Your Portfolio

      October 14, 2025
    • CHARBONE signe une entente d’approvisionnement en hydrogene propre a UHP d’une duree de 5 ans en Ontario, marquant une etape majeure dans son expansion commerciale

      October 14, 2025
    • CHARBONE Signs Five-Year Clean UHP Hydrogen Supply Agreement in Ontario, Marking a Major Milestone in its Commercial Expansion

      October 14, 2025
    • Copper Quest Amends RIP Cu-Mo Option Agreement and Provides Project Update

      October 14, 2025
    • Skyharbour’s Partner North Shore Uranium Completes Prospecting Program at the Falcon Project; Significant Radioactivity Discovered in Outcrops and Boulders

      October 14, 2025
    • About us
    • Contacts
    • Privacy Policy
    • Terms and Conditions
    • Email Whitelisting

    Disclaimer: globalinvestmentpulse.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 globalinvestmentpulse.com | All Rights Reserved

    Global Investment Pulse
    • Investing
    • Stock
    • Business
    • Politics